Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Buyang Huanwu Decoction With Wuling Powder for Acute Ischemic Stroke (BYHW-WL)

3 juli 2026 uppdaterad av: Changchuan Bai, Liaoning University of Traditional Chinese Medicine

Buyang Huanwu Decoction Combined With Wuling Powder as Adjunctive Therapy for Acute Ischemic Stroke: A Randomized, Assessor-Blinded, Controlled Clinical Study

Acute ischemic stroke is a common cause of disability. Standard Western medical treatment is widely used, but some patients continue to have neurological impairment and difficulty with daily activities after stroke.

This study evaluated whether Buyang Huanwu Decoction combined with Wuling Powder, when added to standard Western medical treatment, could help improve recovery in patients with acute ischemic stroke. Eligible patients were randomly assigned to receive either standard Western medical treatment alone or standard Western medical treatment plus Buyang Huanwu Decoction combined with Wuling Powder for 14 days.

The study assessed neurological function, activities of daily living, disability outcomes, and short-term safety. Blood samples were also collected to explore changes in serum metabolites and redox-related biomarkers that may be related to treatment response. A non-stroke reference group was included only for serum metabolomic comparison and was not part of the randomized treatment comparison.

Studieöversikt

Detaljerad beskrivning

This single-center, randomized, assessor-blinded, controlled clinical study was designed to evaluate Buyang Huanwu Decoction combined with Wuling Powder as an adjunct to standard Western medical treatment in patients with acute ischemic stroke.

Eligible patients with acute ischemic stroke were randomly assigned to receive standard Western medical treatment alone or standard Western medical treatment plus Buyang Huanwu Decoction combined with Wuling Powder for 14 days. Because the intervention involved an oral herbal decoction, participant blinding was not feasible. Clinical outcome assessors, laboratory technicians, and metabolomics analysts were blinded to group allocation.

The clinical part of the study focused on neurological function, activities of daily living, disability outcomes, and short-term safety. These were assessed using the National Institutes of Health Stroke Scale, Barthel Index, modified Rankin Scale, and adverse event monitoring.

The exploratory mechanistic part of the study examined serum drug-derived constituents, untargeted serum metabolomic profiles, and redox-related biomarkers. Serum samples were collected from patients with acute ischemic stroke before and after treatment. A non-stroke reference group provided serum samples for metabolomic comparison only and was not included in the randomized treatment comparison.

Studietyp

Interventionell

Inskrivning (Faktisk)

102

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Liaoning
      • Shenyang, Liaoning, Kina, 110034
        • The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Ja

Beskrivning

Inclusion Criteria:

Clinical diagnosis of acute ischemic stroke confirmed by CT or MRI Age 40-75 years (stroke group) Age 20-75 years (non-stroke reference group) Enrollment within 7 days of symptom onset NIHSS score 4-22 mRS score 2-4 First-ever ischemic stroke or prior infarction without baseline disability No intravenous thrombolysis, thrombectomy, or vascular stenting Written informed consent obtained

Exclusion Criteria:

Transient ischemic attack or hemorrhagic stroke Subarachnoid hemorrhage or vascular malformation Lacunar infarction or large infarction with severe edema Non-atherothrombotic stroke causes (tumor, trauma, metabolic, parasitic, rheumatic heart disease) Severe cardiac, hepatic, renal, hematologic, or endocrine disease Severe psychiatric or cognitive impairment Severe physical disability affecting evaluation Pregnancy or lactation Drug allergy or bleeding tendency Participation in other clinical trials within 4 weeks Progressive stroke Use of organ-damaging drugs within 4 weeks

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Standard Western Medical Treatment
Participants received standard Western medical treatment for acute ischemic stroke according to clinical guidelines, including antiplatelet therapy, lipid-lowering therapy, plaque stabilization, neuroprotective treatment, and management of blood pressure and blood glucose.
Standard guideline-based medical care for acute ischemic stroke.
Guideline-based acute ischemic stroke management.
Experimentell: Buyang Huanwu Decoction Combined With Wuling Powder Plus Standard Western Medical Treatment
Participants received Buyang Huanwu Decoction combined with Wuling Powder in addition to standard Western medical treatment for 14 days.
Standard guideline-based medical care for acute ischemic stroke.
Guideline-based acute ischemic stroke management.
14-day oral decoction, twice daily, composed of Astragali Radix, Angelicae Sinensis Radix, and other herbs as specified.
Sham Comparator: Non-Stroke Metabolomic Reference Group
Participants provided serum samples only for metabolomic comparison and did not receive any therapeutic intervention. This group was not part of the randomized treatment allocation.
Blood samples collected for metabolomic profiling only.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in National Institutes of Health Stroke Scale (NIHSS; 0-42) score from baseline to Day 14
Tidsram: Baseline and Day 14

The National Institutes of Health Stroke Scale was used to assess neurological deficit severity in patients with acute ischemic stroke. Scores were assessed before treatment and after 14 days of treatment. A lower score indicates less severe neurological impairment.

Scale: 0-42 Higher score = worse neurological deficit Lower score = improvement

Baseline and Day 14
Change in Barthel Index (0-100) score from baseline to Day 14
Tidsram: Baseline and Day 14
Range: 0-100 Higher score = better activities of daily living The Barthel Index was used to assess activities of daily living in patients with acute ischemic stroke. Scores were assessed before treatment and after 14 days of treatment. A higher score indicates better ability to perform activities of daily living.
Baseline and Day 14
Change in modified Rankin Scale (mRS; 0-6) score from baseline to Day 14
Tidsram: Baseline and Day 14
Range: 0-6 Higher score = worse disability The modified Rankin Scale was used to assess disability outcome in patients with acute ischemic stroke. Scores were assessed before treatment and after 14 days of treatment. A lower score indicates less disability.
Baseline and Day 14

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Modified Rankin Scale Score at 90 Days After Stroke Onset
Tidsram: 90 days after stroke onset
The modified Rankin Scale was assessed at 90 days after stroke onset to evaluate longer-term functional outcome. A lower score indicates less disability.
90 days after stroke onset
Incidence of Adverse Events During the Treatment Period
Tidsram: Baseline to Day 14
Safety was assessed by monitoring adverse events during the treatment period. The incidence, type, severity, duration, management, and outcome of adverse events were recorded.
Baseline to Day 14
Change in serum MMP-9 (ng/mL) from baseline to Day 14
Tidsram: Baseline, Day 14
Serum MMP-9 levels were measured at baseline and Day 14 using ELISA.
Baseline, Day 14
Change in serum superoxide dismutase (SOD; U/mL) from baseline to Day 14
Tidsram: Baseline, Day 14
Serum SOD levels were measured at baseline and Day 14 using ELISA.
Baseline, Day 14
Change in serum malondialdehyde (MDA; nmol/mL) from baseline to Day 14
Tidsram: Baseline, Day 14
Serum MDA levels were measured at baseline and Day 14 using ELISA.
Baseline, Day 14
Change in serum malondialdehyde (HO-1 (ng/mL)) from baseline to Day 14
Tidsram: Baseline, Day 14
Serum HO-1 levels were measured at baseline and Day 14 using ELISA.
Baseline, Day 14
Change in serum malondialdehyde (Keap1 (ng/mL)) from baseline to Day 14
Tidsram: Baseline, Day 14
Serum Keap1 levels were measured at baseline and Day 14 using ELISA.
Baseline, Day 14
Change in serum superoxide dismutase (NQO1 (ng/mL)) from baseline to Day 14
Tidsram: Baseline, Day 14
Serum NQO1 levels were measured at baseline and Day 14 using ELISA.
Baseline, Day 14
Change in serum malondialdehyde (Nrf2 (ng/mL)) from baseline to Day 14
Tidsram: Baseline, Day 14
Serum Nrf2 levels were measured at baseline and Day 14 using ELISA.
Baseline, Day 14
Serum metabolomic profile changes from baseline to Day 14
Tidsram: Baseline, Day 14
Serum metabolomic profiles were analyzed using ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry. Untargeted metabolomics was used to evaluate treatment-associated metabolic changes.
Baseline, Day 14

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

20 mars 2023

Primärt slutförande (Faktisk)

20 april 2025

Avslutad studie (Faktisk)

30 juni 2025

Studieregistreringsdatum

Först inskickad

28 juni 2026

Först inskickad som uppfyllde QC-kriterierna

3 juli 2026

Första postat (Faktisk)

7 juli 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

7 juli 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

3 juli 2026

Senast verifierad

1 juli 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • 2023(XS)-001-02(FS)
  • ethics committee (Registeridentifierare: Universitary Hospital ethics committee of Marrakech)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera